Researchers’ bionic pancreas outperforms standard insulin pump therapy

Share

Researchers' bionic pancreas outperforms standard insulin pump therapyResearchers from Boston University have developed a bionic pancreas system that outperformed conventional insulin pump therapy for patients with type 1 diabetes, according to a trial conducted at Massachusetts General Hospital. The team’s work was published in The Lancet. 

This device is the latest development in the race to make an entirely closed loop insulin pump system, or “artificial pancreas” for patients with type 1 diabetes. In September, Medtronic‘s (NYSE:MDT) MiniMed 670G hybrid closed loop system became the 1st device of its kind to win FDA clearance. Boston University has licensed the patents for its system to start-up Beta Bionics, which is developing and commercializing the iLet bionic pancreas.

Get the full story at our sister site, Drug Delivery Business News.

Want to stay on top of MDO content? Subscribe to our e-newsletter.

Speak Your Mind

*